Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

37.5%

3 terminated/withdrawn out of 8 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
6(75.0%)
Phase 3
2(25.0%)
8Total
Phase 2(6)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT04044313Phase 2Completed

HAIC Plus Lenvatinib and Toripalimab for Advanced HCC

Role: lead

NCT05886257Phase 2Withdrawn

Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

Role: lead

NCT05760599Phase 2Unknown

Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

Role: lead

NCT04961970Phase 3Unknown

HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC

Role: lead

NCT04044651Phase 2Withdrawn

Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection

Role: lead

NCT03771846Phase 3Unknown

HAIC Versus Systemic Chemotherapy for Unresectable ICC

Role: lead

NCT03775707Phase 2Withdrawn

Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria

Role: lead

NCT03779100Phase 2Suspended

Lenvatinib Plus PD-1 Antibody for Unresectable ICC

Role: lead

All 8 trials loaded